David LeBlond

968 total citations
32 papers, 463 citations indexed

About

David LeBlond is a scholar working on Statistics, Probability and Uncertainty, Statistics and Probability and Molecular Biology. According to data from OpenAlex, David LeBlond has authored 32 papers receiving a total of 463 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Statistics, Probability and Uncertainty, 10 papers in Statistics and Probability and 7 papers in Molecular Biology. Recurrent topics in David LeBlond's work include Advanced Statistical Process Monitoring (11 papers), Statistical Methods in Clinical Trials (8 papers) and Drug Solubulity and Delivery Systems (3 papers). David LeBlond is often cited by papers focused on Advanced Statistical Process Monitoring (11 papers), Statistical Methods in Clinical Trials (8 papers) and Drug Solubulity and Delivery Systems (3 papers). David LeBlond collaborates with scholars based in United States, United Kingdom and Germany. David LeBlond's co-authors include Mary Saltarelli, Michael Decker, Charles D. Mills, Shailen K. Joshi, Michaël Meyer, Peer B. Jacobson, Gin C. Hsieh, Chang Zhu, Czeslaw Radziejewski and David Ouellette and has published in prestigious journals such as Analytical Biochemistry, Neuroscience and Clinical Chemistry.

In The Last Decade

David LeBlond

29 papers receiving 446 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David LeBlond United States	11	193	111	101	48	37	32	463
Mengjing Zhao China	13	175 0.9×	131 1.2×	31 0.3×	23 0.5×	56 1.5×	33	506
Yuehua Xu China	17	144 0.7×	25 0.2×	101 1.0×	90 1.9×	109 2.9×	30	693
Deepika Shukla India	15	161 0.8×	109 1.0×	76 0.8×	9 0.2×	17 0.5×	45	618
María C. Moreno Argentina	14	233 1.2×	37 0.3×	54 0.5×	30 0.6×	18 0.5×	25	520
Lishan Lin China	16	446 2.3×	72 0.6×	49 0.5×	32 0.7×	53 1.4×	49	876
Ksenia Blinova United States	19	615 3.2×	72 0.6×	36 0.4×	51 1.1×	23 0.6×	36	1.1k
Gurjinder Kaur United States	12	192 1.0×	146 1.3×	45 0.4×	23 0.5×	9 0.2×	29	552
Huailei Jiang United States	16	125 0.6×	87 0.8×	156 1.5×	16 0.3×	65 1.8×	32	684
Sandra Lynch United States	10	185 1.0×	49 0.4×	88 0.9×	26 0.5×	28 0.8×	11	449
Jun-Ichi Goto Japan	14	460 2.4×	39 0.4×	23 0.2×	28 0.6×	35 0.9×	39	866

Countries citing papers authored by David LeBlond

Since Specialization

Citations

This map shows the geographic impact of David LeBlond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David LeBlond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David LeBlond more than expected).

Fields of papers citing papers by David LeBlond

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David LeBlond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David LeBlond. The network helps show where David LeBlond may publish in the future.

Co-authorship network of co-authors of David LeBlond

This figure shows the co-authorship network connecting the top 25 collaborators of David LeBlond. A scholar is included among the top collaborators of David LeBlond based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David LeBlond. David LeBlond is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mockus, Linas, David LeBlond, Xu Sun, et al.. (2022). Bayesian statistical approaches to drug product variability assessment and release. International Journal of Pharmaceutics. 624. 122037–122037.

LeBlond, David, et al.. (2022). DISSOLUTION PROFILE SIMILARITY ANALYSES—STATISTICAL PRINCIPLES, METHODS AND CONSIDERATIONS. The AAPS Journal. 24(3). 54–54. 9 indexed citations

Suarez‐Sharp, Sandra, et al.. (2020). In Vitro Dissolution Profiles Similarity Assessment in Support of Drug Product Quality: What, How, When—Workshop Summary Report. The AAPS Journal. 22(4). 74–74. 21 indexed citations

Mockus, Linas, Gintaras V. Reklaitis, Kenneth R. Morris, & David LeBlond. (2019). Risk-Based Approach to Lot Release. Journal of Pharmaceutical Sciences. 109(2). 1035–1042. 2 indexed citations

Burdick, Richard K., et al.. (2018). Simple Approach to Calculate Random Effects Model Tolerance Intervals to Set Release and Shelf-Life Specification Limits of Pharmaceutical Products. PDA Journal of Pharmaceutical Science and Technology. 73(1). 39–59. 6 indexed citations

Christopher, David, David LeBlond, Mengjie Liu, et al.. (2017). Evaluating Current Practices in Shelf Life Estimation. AAPS PharmSciTech. 19(2). 668–680. 7 indexed citations

Yang, Harry, Steven Novick, & David LeBlond. (2014). Testing Assay Linearity Over a Pre-Specified Range. Journal of Biopharmaceutical Statistics. 25(2). 339–350. 3 indexed citations

Ouellette, David, et al.. (2012). Increased serum clearance of oligomannose species present on a human IgG1 molecule. mAbs. 4(4). 509–520. 102 indexed citations

Mills, Charles D., David LeBlond, Shailen K. Joshi, et al.. (2012). Estimating Efficacy and Drug ED50's Using von Frey Thresholds: Impact of Weber's Law and Log Transformation. Journal of Pain. 13(6). 519–523. 96 indexed citations

10.

Mockus, Linas, David LeBlond, Prabir K. Basu, Rakhi B. Shah, & Mansoor A. Khan. (2011). A QbD Case Study: Bayesian Prediction of Lyophilization Cycle Parameters. AAPS PharmSciTech. 12(1). 442–448. 8 indexed citations

11.

Day, Mark L., Prem K.G. Chandran, Feng Luo, et al.. (2011). Latrepirdine increases cerebral glucose utilization in aged mice as measured by [18F]-fluorodeoxyglucose positron emission tomography. Neuroscience. 189. 299–304. 11 indexed citations

12.

LeBlond, David. (2010). FDA Bayesian Statistics Guidance for Medical Device Clinical Trials—Application to Process Validation. 5 indexed citations

13.

LeBlond, David. (2008). Using Probability Distributions to Make Decisions. 14(3). 14–26. 1 indexed citations

14.

LeBlond, David. (2008). Estimation : Knowledge Building with Probability Distributions. 14(4). 27–42.

15.

Liu, Xuesong, Joann P. Palma, Robert J. Kinders, et al.. (2008). An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors. Analytical Biochemistry. 381(2). 240–247. 32 indexed citations

16.

LeBlond, David, et al.. (2001). Unit Dose Sampling and Final Product Performance: An Alternative Approach. Drug Development and Industrial Pharmacy. 27(7). 731–743. 2 indexed citations

17.

LeBlond, David, et al.. (1998). Control Improvement for Advanced Construction Equipment. Journal of Construction Engineering and Management. 124(4). 289–296. 11 indexed citations

18.

Parsons, Robert G., et al.. (1993). Multianalyte assay system developed for drugs of abuse.. PubMed. 39(9). 1899–903. 21 indexed citations

19.

Parsons, Robert G., et al.. (1993). Multianalyte assay system developed for drugs of abuse. Clinical Chemistry. 39(9). 1899–1903. 15 indexed citations

20.

LeBlond, David, Curtis L. Ashendel, & W.A. Wood. (1980). Determination of enzyme kinetic parameters by continuous addition of substrate to a single reaction mixture and analysis by a tangent-slope procedure. Analytical Biochemistry. 104(2). 355–369. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact